ALLMedicine™ Epileptic Encephalopathies Center

Jun 25th, 2022 - To evaluate the effectiveness and tolerability of clobazam therapy in the pediatric population in terms of seizure semiology, epileptic syndromes, and etiological subgroups. A retrospective cohort study was conducted consisting of 1710 epileptic c...

Jun 21st, 2022 - We assessed the frequency of pediatric monogenic epilepsies and precision therapies at a tertiary epilepsy center. We analyzed medical records of children, born in 2006-2011 and followed at the Danish Epilepsy Center from January to December 2015;...

Jun 10th, 2022 - The developmental and epileptic encephalopathies (DEEs) are the most severe group of epilepsies which co-present with developmental delay and intellectual disability (ID). DEEs usually occur in people without a family history of epilepsy and have ...

Jun 3rd, 2022 - 17p13.1-2 microdeletion syndrome is a congenital anomaly syndrome with characteristic facial features and multiple malformations. The prevalence of epilepsy with 17p13.1-2 microdeletion is low, with only one case reported for late-onset spasms. La...

May 19th, 2022 - This is a randomized, double-blind, parallel-group, dose-escalation, placebo-controlled study of LP352 in adults with developmental and epileptic encephalopathies (DEE) with an average of ≥ 4 observed/countable motor seizures per 4-week period dur...

May 19th, 2022 - This is a randomized, double-blind, parallel-group, dose-escalation, placebo-controlled study of LP352 in adults with developmental and epileptic encephalopathies (DEE) with an average of ≥ 4 observed/countable motor seizures per 4-week period dur...

May 16th, 2022 - This prospective, longitudinal, natural history master protocol has been designed to define the seizure, neurodevelopmental, and behavioral characteristics of SCN1A-positive Dravet Syndrome in infants and children between 6 and 60 months. It will ...

Mar 16th, 2022 - This study is a pilot non-controlled clinical trial with adjunctive fenfluramine for the treatment of five different types of developmental and epileptic encephalopathies (DEEs) focused on epileptic and "non-epileptic outcomes": SYNGAP1 and STXBP1...

Nov 17th, 2021 - Most cardiac studies have investigated patients with intractable focal epilepsy who have a high risk for co-morbidities, accidents, injury and SUDEP. This is confounded by the major antiepileptic drug burden in this population. Very little, howeve...

Sep 28th, 2021 - Epileptic Encephalopathies are a group of epilepsies that develop in children. These epilepsies can cause frequent and difficult to control seizures. Because of the ongoing seizures, these epilepsies can also cause cognitive impairment and neurolo...

Mar 29th, 2022 - The US Food and Drug Administration (FDA) has approved fenfluramine (Fintepla) oral solution, a Schedule IV controlled substance, for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children aged 2 years and older, the c...

Sep 16th, 2021 - Topical cannabidiol (CBD) gel, added to antiseizure medication, may help reduce seizures and improve quality of life in children with developmental and epileptic encephalopathies, according to the results of a nonrandomized controlled trial. Devel...

Oct 29th, 2019 - The Rare Pediatric Diseases Special Report is a supplement to Pediatric News that discusses advancements in the treatment of rare pediatric neuromuscular disorders like spinal muscular atrophy, Duchenne muscular dystrophy, and X-linked myotubular.

Aug 14th, 2019 - BANGKOK – For a form of epilepsy treatment that’s been around since the 1920s, ketogenic diet therapy has lately been the focus of a surprising wealth of clinical research and development, Suvasini Sharma, MD, observed at the International Epileps.

Jun 19th, 2019 - Although people with refractory epilepsy, including some with frequent, ongoing convulsive seizures, are at high risk for sudden unexpected death in epilepsy (SUDEP), a large North American registry study reveals that even those with well-controll...